Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Arthritis, Rheumatoid × Adrenal Cortex Hormones × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2 Urogenital Neoplasms 1 Neoplasms 1 Multiple Myeloma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Genital Neoplasms, Male 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Methotrexate 9 tocilizumab 5 Rituximab 5 Adalimumab 4 tofacitinib 3 olokizumab 3 Etanercept 3 golimumab 2 RC-18 2 Abatacept 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 baricitinib 1 andecaliximab 1 Tumor Necrosis Factor Inhibitors 1 Sulfasalazine 1 Pharmaceutical Preparations 1 Leflunomide 1 Interleukin 1 Receptor Antagonist Protein 1 Infliximab 1 ISIS104838 1 Hydroxychloroquine 1 Folic Acid 1 Double-Blind Method 1 Chloroquine 1 CT-P13 1 Azathioprine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02046603 2018-12-07

ACT-MOVE

Hoffmann-La Roche

Phase 3 Completed

162 enrolled 30 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡